25 XP   0   0   10

Sopharma AD
Buy, Hold or Sell?

Let's analyse Sopharma AD together

PenkeI guess you are interested in Sopharma AD. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sopharma AD. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sopharma AD

I send you an email if I find something interesting about Sopharma AD.

Quick analysis of Sopharma AD (30 sec.)










What can you expect buying and holding a share of Sopharma AD? (30 sec.)

How much money do you get?

How much money do you get?
zł0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
zł4.73
Expected worth in 1 year
zł4.95
How sure are you?
76.9%

+ What do you gain per year?

Total Gains per Share
zł0.22
Return On Investment
1.6%

For what price can you sell your share?

Current Price per Share
zł13.40
Expected price per share
zł12.70 - zł14.75
How sure are you?
50%

1. Valuation of Sopharma AD (5 min.)




Live pricePrice per Share (EOD)

zł13.40

2. Growth of Sopharma AD (5 min.)




Is Sopharma AD growing?

Current yearPrevious yearGrowGrow %
How rich?$187.1m$175.2m$7.8m4.3%

How much money is Sopharma AD making?

Current yearPrevious yearGrowGrow %
Making money0.000.000.00?
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Sopharma AD (5 min.)




4. Comparing to competitors in the Medical Distribution industry (5 min.)




  Industry Rankings (Medical Distribution)  

What can you expect buying and holding a share of Sopharma AD? (5 min.)

Welcome investor! Sopharma AD's management wants to use your money to grow the business. In return you get a share of Sopharma AD.

What can you expect buying and holding a share of Sopharma AD?

First you should know what it really means to hold a share of Sopharma AD. And how you can make/lose money.

Speculation

The Price per Share of Sopharma AD is zł13.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sopharma AD.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sopharma AD, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is zł4.73. Based on the TTM, the Book Value Change Per Share is zł0.05 per quarter. Based on the YOY, the Book Value Change Per Share is zł0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is zł0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sopharma AD.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Book Value Change Per Share0.030.2%0.010.1%0.020.2%0.090.7%0.090.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.030.2%0.010.1%0.020.2%0.090.7%0.090.7%
Usd Price Per Share3.51-3.16-2.36-2.58-2.58-
Price to Earnings Ratio0.00-0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio104.73-55.38--45.60-16.84-16.84-
Price to Book Ratio2.98-2.74-2.14-2.45-2.45-
Price-to-Total Gains Ratio104.73-55.38--45.60-16.84-16.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.33124
Number of shares300
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.09
Usd Total Gains Per Share0.010.09
Gains per Quarter (300 shares)4.0627.14
Gains per Year (300 shares)16.25108.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10166010999
2033220217208
3049380326317
4065540434426
5081700543535
6098860651644
701141020760753
801301180869862
901461340977971
100163150010861080

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Book Value Change Per Share3.01.00.075.0%9.02.01.075.0%10.02.01.076.9%10.02.01.076.9%10.02.01.076.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share3.01.00.075.0%9.02.01.075.0%10.02.01.076.9%10.02.01.076.9%10.02.01.076.9%

Fundamentals of Sopharma AD

About Sopharma AD

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of the reproductive system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers public opinion research services. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.

Fundamental data was last updated by Penke on 2024-04-05 01:57:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.

1.1. Profitability of Sopharma AD.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sopharma AD earns for each zł1 of revenue.

  • Above 10% is considered healthy but always compare Sopharma AD to the Medical Distribution industry mean.
  • A Net Profit Margin of 0.0% means that zł0.00 for each zł1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sopharma AD:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.2%-2.2%
TTM-2.2%-2.2%
YOY-2.5%-2.5%
5Y-2.3%-2.3%
10Y-2.4%-2.4%
1.1.2. Return on Assets

Shows how efficient Sopharma AD is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sopharma AD to the Medical Distribution industry mean.
  • 0.0% Return on Assets means that Sopharma AD generated zł0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sopharma AD:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.7%-1.7%
TTM-1.7%-1.7%
YOY-1.3%-1.3%
5Y-1.3%-1.3%
10Y-1.7%-1.7%
1.1.3. Return on Equity

Shows how efficient Sopharma AD is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sopharma AD to the Medical Distribution industry mean.
  • 0.0% Return on Equity means Sopharma AD generated zł0.00 for each zł1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sopharma AD:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.4%-4.4%
TTM-4.1%-4.1%
YOY-3.8%-3.8%
5Y-4.1%-4.1%
10Y-4.1%-4.1%

1.2. Operating Efficiency of Sopharma AD.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sopharma AD is operating .

  • Measures how much profit Sopharma AD makes for each zł1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sopharma AD to the Medical Distribution industry mean.
  • An Operating Margin of 0.0% means the company generated zł0.00  for each zł1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sopharma AD:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%-2.9%
TTM-3.0%-3.0%
YOY-3.9%-3.9%
5Y-3.5%-3.5%
10Y-3.4%-3.4%
1.2.2. Operating Ratio

Measures how efficient Sopharma AD is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Distribution industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are zł0.00 for each zł1 in net sales.

Let's take a look of the Operating Ratio trends of Sopharma AD:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.642-1.642
TTM-1.594-1.594
YOY-1.431-1.431
5Y-1.365-1.365
10Y-1.229-1.229

1.3. Liquidity of Sopharma AD.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sopharma AD is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Distribution industry mean).
  • A Current Ratio of 1.29 means the company has zł1.29 in assets for each zł1 in short-term debts.

Let's take a look of the Current Ratio trends of Sopharma AD:

  • The MRQ is 1.287. The company is just able to pay all its short-term debts.
  • The TTM is 1.320. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.287TTM1.320-0.033
TTM1.320YOY1.464-0.144
TTM1.3205Y1.329-0.009
5Y1.32910Y1.3290.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2871.389-0.102
TTM1.3201.400-0.080
YOY1.4641.424+0.040
5Y1.3291.411-0.082
10Y1.3291.371-0.042
1.3.2. Quick Ratio

Measures if Sopharma AD is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sopharma AD to the Medical Distribution industry mean.
  • A Quick Ratio of 0.39 means the company can pay off zł0.39 for each zł1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sopharma AD:

  • The MRQ is 0.388. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.519. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.388TTM0.519-0.131
TTM0.519YOY0.688-0.169
TTM0.5195Y0.592-0.073
5Y0.59210Y0.5920.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3880.746-0.358
TTM0.5190.745-0.226
YOY0.6880.798-0.110
5Y0.5920.784-0.192
10Y0.5920.850-0.258

1.4. Solvency of Sopharma AD.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sopharma AD assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sopharma AD to Medical Distribution industry mean.
  • A Debt to Asset Ratio of 0.50 means that Sopharma AD assets are financed with 50.1% credit (debt) and the remaining percentage (100% - 50.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sopharma AD:

  • The MRQ is 0.501. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.474. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.501TTM0.474+0.028
TTM0.474YOY0.428+0.046
TTM0.4745Y0.4740.000
5Y0.47410Y0.4740.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5010.609-0.108
TTM0.4740.606-0.132
YOY0.4280.600-0.172
5Y0.4740.580-0.106
10Y0.4740.586-0.112
1.4.2. Debt to Equity Ratio

Measures if Sopharma AD is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sopharma AD to the Medical Distribution industry mean.
  • A Debt to Equity ratio of 102.7% means that company has zł1.03 debt for each zł1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sopharma AD:

  • The MRQ is 1.027. The company is able to pay all its debts with equity. +1
  • The TTM is 0.923. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.027TTM0.923+0.103
TTM0.923YOY0.760+0.163
TTM0.9235Y0.932-0.009
5Y0.93210Y0.9320.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0271.554-0.527
TTM0.9231.554-0.631
YOY0.7601.688-0.928
5Y0.9321.675-0.743
10Y0.9321.759-0.827

2. Market Valuation of Sopharma AD

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every zł1 in earnings Sopharma AD generates.

  • Above 15 is considered overpriced but always compare Sopharma AD to the Medical Distribution industry mean.
  • A PE ratio of 0.00 means the investor is paying zł0.00 for every zł1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sopharma AD:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.424-14.424
TTM-15.740-15.740
YOY-18.755-18.755
5Y-15.472-15.472
10Y-19.379-19.379
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sopharma AD:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.097-11.097
TTM-12.349-12.349
YOY-5.253-5.253
5Y-5.122-5.122
10Y-4.874-4.874
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sopharma AD is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Distribution industry mean).
  • A PB ratio of 2.98 means the investor is paying zł2.98 for each zł1 in book value.

Let's take a look of the Price to Book Ratio trends of Sopharma AD:

  • The EOD is 2.832. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.980. Based on the equity, the company is underpriced. +1
  • The TTM is 2.743. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.832MRQ2.980-0.148
MRQ2.980TTM2.743+0.238
TTM2.743YOY2.141+0.602
TTM2.7435Y2.445+0.297
5Y2.44510Y2.4450.000
Compared to industry (Medical Distribution)
PeriodCompanyIndustry (mean)+/- 
EOD2.8320.958+1.874
MRQ2.9801.156+1.824
TTM2.7431.156+1.587
YOY2.1411.207+0.934
5Y2.4451.257+1.188
10Y2.4451.922+0.523
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Sopharma AD compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1350.054+147%0.093+45%0.364-63%0.364-63%
Book Value Per Share--4.7314.628+2%4.429+7%4.239+12%4.239+12%
Current Ratio--1.2871.320-3%1.464-12%1.329-3%1.329-3%
Debt To Asset Ratio--0.5010.474+6%0.428+17%0.474+6%0.474+6%
Debt To Equity Ratio--1.0270.923+11%0.760+35%0.932+10%0.932+10%
Dividend Per Share----0%-0%-0%-0%
Eps----0%-0%-0%-0%
Gross Profit Margin----0%-0%-0%-0%
Market Cap2132100800.000-5%2243482612.2002020723253.050+11%1508381760.000+49%1651950004.015+36%1651950004.015+36%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.832-5%2.9802.743+9%2.141+39%2.445+22%2.445+22%
Pe Ratio----0%-0%-0%-0%
Price Per Share13.400-5%14.10012.700+11%9.480+49%10.382+36%10.382+36%
Price To Free Cash Flow Ratio----0%-0%-0%-0%
Price To Total Gains Ratio99.529-5%104.72955.378+89%-45.600+144%16.841+522%16.841+522%
Quick Ratio--0.3880.519-25%0.688-44%0.592-34%0.592-34%
Return On Assets----0%-0%-0%-0%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share--0.1350.054+147%0.093+45%0.364-63%0.364-63%
Usd Book Value--187148068.800183054310.450+2%175209178.100+7%167691217.692+12%167691217.692+12%
Usd Book Value Change Per Share--0.0330.014+147%0.023+45%0.090-63%0.090-63%
Usd Book Value Per Share--1.1761.150+2%1.101+7%1.054+12%1.054+12%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps----0%-0%-0%-0%
Usd Free Cash Flow----0%-0%-0%-0%
Usd Market Cap530040258.880-5%557729777.393502351800.708+11%374983705.536+49%410674770.998+36%410674770.998+36%
Usd Price Per Share3.331-5%3.5053.157+11%2.357+49%2.581+36%2.581+36%
Usd Profit----0%-0%-0%-0%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.0330.014+147%0.023+45%0.090-63%0.090-63%
 EOD+2 -4MRQTTM+11 -6YOY+11 -65Y+7 -1010Y+7 -10

3.2. Fundamental Score

Let's check the fundamental score of Sopharma AD based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Book Ratio (EOD)Between0-12.832
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.388
Current Ratio (MRQ)Greater than11.287
Debt to Asset Ratio (MRQ)Less than10.501
Debt to Equity Ratio (MRQ)Less than11.027
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.000
Total2/9 (22.2%)

3.3. Technical Score

Let's check the technical score of Sopharma AD based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose13.400
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in BGN. All numbers in thousands.

Summary
Total Assets1,509,892
Total Liabilities757,084
Total Stockholder Equity737,539
 As reported
Total Liabilities 757,084
Total Stockholder Equity+ 737,539
Total Assets = 1,509,892

Assets

Total Assets1,509,892
Total Current Assets781,894
Long-term Assets727,998
Total Current Assets
Cash And Cash Equivalents 128,795
Net Receivables 235,915
Inventory 331,438
Total Current Assets  (as reported)781,894
Total Current Assets  (calculated)696,148
+/- 85,746
Long-term Assets
Property Plant Equipment 357,363
Goodwill 3,439
Intangible Assets 57,720
Long-term Assets  (as reported)727,998
Long-term Assets  (calculated)418,522
+/- 309,476

Liabilities & Shareholders' Equity

Total Current Liabilities607,710
Long-term Liabilities149,374
Total Stockholder Equity737,539
Total Current Liabilities
Short Long Term Debt 207,502
Accounts payable 187,649
Other Current Liabilities 14,123
Total Current Liabilities  (as reported)607,710
Total Current Liabilities  (calculated)409,274
+/- 198,436
Long-term Liabilities
Long term Debt 55,529
Capital Lease Obligations Min Short Term Debt84,780
Long-term Liabilities Other 5,543
Long-term Liabilities  (as reported)149,374
Long-term Liabilities  (calculated)145,852
+/- 3,522
Total Stockholder Equity
Retained Earnings 395,069
Total Stockholder Equity (as reported)737,539
Total Stockholder Equity (calculated)395,069
+/- 342,470
Other
Capital Stock172,591
Common Stock Shares Outstanding 159,112
Net Debt 134,236
Net Invested Capital 1,000,570
Net Working Capital 174,184
Property Plant and Equipment Gross 682,098



Balance Sheet

Currency in BGN. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-31
> Total Assets 
1,242,112
0
1,224,794
1,230,571
1,204,978
1,198,748
1,215,889
1,253,510
1,255,799
1,311,711
1,349,195
1,439,574
1,509,892
1,509,8921,439,5741,349,1951,311,7111,255,7991,253,5101,215,8891,198,7481,204,9781,230,5711,224,79401,242,112
   > Total Current Assets 
611,920
599,574
605,827
619,252
571,232
564,467
579,284
582,394
578,377
621,373
653,959
729,491
781,894
781,894729,491653,959621,373578,377582,394579,284564,467571,232619,252605,827599,574611,920
       Cash And Cash Equivalents 
25,102
0
20,483
22,153
37,677
20,386
18,938
17,798
19,654
19,615
16,911
17,339
128,795
128,79517,33916,91119,61519,65417,79818,93820,38637,67722,15320,483025,102
       Net Receivables 
280,918
280,118
282,027
305,057
258,740
269,268
273,927
276,035
264,103
290,443
305,229
239,828
235,915
235,915239,828305,229290,443264,103276,035273,927269,268258,740305,057282,027280,118280,918
       Inventory 
287,973
280,824
285,025
274,270
255,949
256,267
269,529
272,917
279,086
296,002
315,928
311,599
331,438
331,438311,599315,928296,002279,086272,917269,529256,267255,949274,270285,025280,824287,973
       Other Current Assets 
15,735
14,680
15,996
15,784
16,125
15,856
14,135
13,827
12,797
12,822
13,011
0
0
0013,01112,82212,79713,82714,13515,85616,12515,78415,99614,68015,735
   > Long-term Assets 
629,935
0
618,967
611,319
633,746
634,281
636,605
671,116
677,422
690,338
695,236
710,083
727,998
727,998710,083695,236690,338677,422671,116636,605634,281633,746611,319618,9670629,935
       Property Plant Equipment 
395,781
383,748
381,490
377,543
362,393
359,557
358,261
376,356
376,263
374,545
370,185
363,220
357,363
357,363363,220370,185374,545376,263376,356358,261359,557362,393377,543381,490383,748395,781
       Goodwill 
13,269
0
13,360
13,417
13,420
13,337
13,439
13,267
3,522
3,499
3,499
3,533
3,439
3,4393,5333,4993,4993,52213,26713,43913,33713,42013,41713,360013,269
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000
       Intangible Assets 
58,272
0
55,940
54,823
54,421
52,436
50,946
49,616
48,151
47,175
47,175
45,350
57,720
57,72045,35047,17547,17548,15149,61650,94652,43654,42154,82355,940058,272
       Accumulated depreciation 
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000
       Other Assets 
86,597
83,902
83,278
73,406
70,414
72,288
71,763
72,893
82,004
90,081
92,664
0
0
0092,66490,08182,00472,89371,76372,28870,41473,40683,27883,90286,597
> Total Liabilities 
675,517
0
627,624
615,246
546,110
519,330
516,050
531,763
537,669
562,057
637,679
708,189
757,084
757,084708,189637,679562,057537,669531,763516,050519,330546,110615,246627,6240675,517
   > Total Current Liabilities 
543,597
513,033
487,973
492,397
423,892
392,178
395,049
390,470
396,562
430,902
509,724
575,297
607,710
607,710575,297509,724430,902396,562390,470395,049392,178423,892492,397487,973513,033543,597
       Short Long Term Debt 
286,453
0
228,304
213,638
226,859
192,238
185,370
183,188
156,383
172,021
206,228
285,904
207,502
207,502285,904206,228172,021156,383183,188185,370192,238226,859213,638228,3040286,453
       Accounts payable 
163,857
158,683
173,012
189,559
143,635
148,660
156,871
152,738
154,481
179,429
165,014
152,948
187,649
187,649152,948165,014179,429154,481152,738156,871148,660143,635189,559173,012158,683163,857
       Other Current Liabilities 
16,395
17,768
14,923
17,230
9,371
11,893
11,230
14,273
40,201
36,774
96,755
11,250
14,123
14,12311,25096,75536,77440,20114,27311,23011,8939,37117,23014,92317,76816,395
   > Long-term Liabilities 
131,066
0
139,651
122,849
122,218
127,152
121,001
141,293
141,107
131,155
127,955
132,892
149,374
149,374132,892127,955131,155141,107141,293121,001127,152122,218122,849139,6510131,066
       Capital Lease Obligations Min Short Term Debt
67,544
0
62,767
61,490
52,763
54,932
52,753
70,252
83,164
82,543
74,573
84,316
84,780
84,78084,31674,57382,54383,16470,25252,75354,93252,76361,49062,767067,544
       Other Liabilities 
49,870
43,110
42,966
42,669
38,131
37,891
37,665
35,712
31,367
31,685
31,642
0
0
0031,64231,68531,36735,71237,66537,89138,13142,66942,96643,11049,870
> Total Stockholder Equity
553,269
0
584,385
601,424
646,975
665,656
686,947
710,327
706,073
736,289
697,339
716,423
737,539
737,539716,423697,339736,289706,073710,327686,947665,656646,975601,424584,3850553,269
   Common Stock
134,798
134,798
134,798
134,798
134,798
134,798
134,798
134,798
134,798
134,798
134,798
0
0
00134,798134,798134,798134,798134,798134,798134,798134,798134,798134,798134,798
   Retained Earnings 
418,540
439,966
454,214
473,802
508,231
529,199
550,638
572,909
575,980
606,929
571,718
520,824
395,069
395,069520,824571,718606,929575,980572,909550,638529,199508,231473,802454,214439,966418,540
   Accumulated Other Comprehensive Income 0000000000000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000



Balance Sheet

Currency in BGN. All numbers in thousands.




Cash Flow

Currency in BGN. All numbers in thousands.




Income Statement

Currency in BGN. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,874,422
Cost of Revenue-1,469,512
Gross Profit404,910404,910
 
Operating Income (+$)
Gross Profit404,910
Operating Expense-1,778,748
Operating Income95,674-1,373,838
 
Operating Expense (+$)
Research Development0
Selling General Administrative52,042
Selling And Marketing Expenses0
Operating Expense1,778,74852,042
 
Net Interest Income (+$)
Interest Income4,348
Interest Expense-11,129
Other Finance Cost-4,764
Net Interest Income-11,545
 
Pretax Income (+$)
Operating Income95,674
Net Interest Income-11,545
Other Non-Operating Income Expenses0
Income Before Tax (EBT)110,89895,674
EBIT - interestExpense = -11,129
95,207
106,336
Interest Expense11,129
Earnings Before Interest and Taxes (EBIT)0122,027
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax110,898
Tax Provision-11,821
Net Income From Continuing Ops99,07799,077
Net Income95,207
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net011,545
 

Technical Analysis of Sopharma AD
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sopharma AD. The general trend of Sopharma AD is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sopharma AD's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sopharma AD.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 14.40 < 14.40 < 14.75.

The bearish price targets are: 13.05 > 12.70 > 12.70.

Tweet this
Sopharma AD Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sopharma AD. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sopharma AD Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sopharma AD.

Sopharma AD Daily Moving Average Convergence/Divergence (MACD) ChartSopharma AD Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sopharma AD. The current adx is .

Sopharma AD Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sopharma AD.

Sopharma AD Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sopharma AD.

Sopharma AD Daily Relative Strength Index (RSI) ChartSopharma AD Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sopharma AD.

Sopharma AD Daily Stochastic Oscillator ChartSopharma AD Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sopharma AD.

Sopharma AD Daily Commodity Channel Index (CCI) ChartSopharma AD Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sopharma AD.

Sopharma AD Daily Chande Momentum Oscillator (CMO) ChartSopharma AD Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sopharma AD.

Sopharma AD Daily Williams %R ChartSopharma AD Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sopharma AD.

Sopharma AD Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sopharma AD.

Sopharma AD Daily Average True Range (ATR) ChartSopharma AD Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sopharma AD.

Sopharma AD Daily On-Balance Volume (OBV) ChartSopharma AD Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sopharma AD.

Sopharma AD Daily Money Flow Index (MFI) ChartSopharma AD Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sopharma AD.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Sopharma AD Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sopharma AD based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose13.400
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sopharma AD with someone you think should read this too:
  • Are you bullish or bearish on Sopharma AD? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sopharma AD? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sopharma AD

I send you an email if I find something interesting about Sopharma AD.


Comments

How you think about this?

Leave a comment

Stay informed about Sopharma AD.

Receive notifications about Sopharma AD in your mailbox!